IRAK1 and B-cell chronic lymphocytic leukemia: Alternatively, another target for potentially useful novel agents in CLL is the Toll-like receptor (TLR) intracellular signaling pathway, which is open to modification by interleukin-1 receptor-associated kinase (IRAK) inhibitors, monoclonal antibodies, oligonucleotides, lipid-A analogs, and microRNA.